Stock analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Down 6.1 %
Shares of AKTX stock opened at $2.30 on Friday. Akari Therapeutics has a 52-week low of $1.08 and a 52-week high of $4.40. The firm’s 50 day moving average price is $2.87 and its two-hundred day moving average price is $2.83.
About Akari Therapeutics
Read More
- Five stocks we like better than Akari Therapeutics
- What is MarketRank™? How to Use it
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Using the MarketBeat Dividend Tax Calculator
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- How to Read Stock Charts for Beginners
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.